Search

Your search keyword '"Pagotto, U"' showing total 100 results

Search Constraints

Start Over You searched for: Author "Pagotto, U" Remove constraint Author: "Pagotto, U" Topic obesity Remove constraint Topic: obesity
100 results on '"Pagotto, U"'

Search Results

1. Sarcopenic obesity and reduced BMD in young men living with HIV: body composition and sex steroids interplay.

2. How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre.

Catalog

Books, media, physical & digital resources

3. OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions.

4. Effect of clomiphene citrate treatment on the Sertoli cells of dysmetabolic obese men with low testosterone levels.

5. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE).

6. Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism.

7. Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women.

8. Pharmacological management of obesity: an endocrine Society clinical practice guideline.

9. Obesity-related proliferative diseases: the interaction between adipose tissue and estrogens in post-menopausal women.

10. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls.

11. Cross-talk between adipose tissue and the HPA axis in obesity and overt hypercortisolemic states.

12. The unrelenting fall of the pharmacological treatment of obesity.

13. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy.

14. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.

15. Brain PET imaging in obesity and food addiction: current evidence and hypothesis.

16. Energy balance regulation by endocannabinoids at central and peripheral levels.

17. Cortisol, energy intake, and food frequency in overweight/obese women.

18. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome.

19. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance.

20. Stress-related development of obesity and cortisol in women.

21. Feeding disorders and obesity.

22. Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity.

23. [Endocannabinoid system and energy metabolism: physiology and pathophysiology].

24. [Pharmacological therapy of obesity].

25. The endocannabinoid system as a target for obesity treatment.

26. Circulating obestatin levels and the ghrelin/obestatin ratio in obese women.

27. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases.

28. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome.

29. The impact of obesity on reproduction in women with polycystic ovary syndrome.

30. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.

31. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.

32. Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity.

33. Endocannabinoids and energy metabolism.

34. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome.

36. The endocannabinoid system and the treatment of obesity.

37. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors.

38. Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity.

39. Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.

40. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.

41. Ghrelin as a potential anti-obesity target.

42. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.

43. Obesity and the polycystic ovary syndrome.

44. Hormones and pathophysiology of obesity.

47. Behavioral, socio-environmental, educational and demographic correlates of excess body weight in Italian adolescents and young adults.

48. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study

49. The Endocannabinoid System and Energy Metabolism.

50. Cannabinoid Type 1 Receptor: Another Arrow in the Adipocytes’ Bow.